Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

The FDA declined to endorse leucovorin as a treatment for autism, but approved the drug to treat cerebral folate deficiency, ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

That's the purpose of the estimand framework—to define ahead of time, before you even start randomizing patients, everything that can happen, and then define the methods you will use to attenuate the ...

Self-related information automatically modulates early attentional selection into awareness through mechanisms distinct from physical salience, revealing an obligatory, individualized ...

If you enjoy playing endless cards and cycling through your deck in a single turn, you need to play as The Silent in Slay the ...

And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...

Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer inpatients to community dental providers. Objectives: Previous research suggests ...

Kyverna Therapeutics, Inc. ( KYTX) Leerink Global Healthcare Conference 2026 March 9, 2026 11:20 AM EDT ...